Shifts in Lipid-Lowering Treatment for ACS After Insurance Policy Change in China

Overview

This retrospective cohort study analyzed real-world data from Chinese chest pain centers to evaluate changes in lipid-lowering therapy (LLT) patterns for acute coronary syndrome (ACS) patients before and after the 2022 national insurance coverage of PCSK9 inhibitors. The study found increased use of PCSK9 inhibitors and combination therapies post-policy, with implications for improved LDL-C target attainment.

Background

Acute coronary syndromes (ACS) are a leading cause of mortality worldwide, with lipid-lowering therapy (LLT) being essential to reduce low-density lipoprotein cholesterol (LDL-C) and improve outcomes. Despite guideline recommendations for intensive LLT, many post-ACS patients fail to reach LDL-C targets, partly due to underuse of non-statin therapies such as PCSK9 inhibitors. In China, PCSK9 inhibitors were costly and not covered by insurance until January 2022, when national healthcare insurance began reimbursing these agents at reduced prices, potentially altering treatment patterns.

Data Highlights

Key Findings

• Post-ACS patients in China showed increased use of PCSK9 inhibitors after insurance reimbursement began in 2022.
• Combination LLT regimens including moderate-intensity statins plus PCSK9 inhibitors or ezetimibe became more common following policy change.
• LDL-C goal attainment rates improved at 1- and 3-month follow-ups after discharge in the post-policy cohort.
• Insurance coverage significantly reduced the cost barrier for PCSK9 inhibitors, facilitating broader access.
• The study leveraged a large, prospective national database covering 4441 chest pain centers across 31 provinces, enhancing generalizability.

Clinical Implications

The introduction of national insurance coverage for PCSK9 inhibitors in China has led to increased adoption of intensive lipid-lowering strategies in ACS patients, potentially improving LDL-C target achievement and cardiovascular outcomes. Clinicians should consider combination LLT regimens, including PCSK9 inhibitors, especially for very high-risk patients, to optimize secondary prevention. Policymakers should recognize the impact of reimbursement policies on treatment accessibility and adherence.

Conclusion

The 2022 national insurance policy change in China substantially shifted lipid-lowering treatment patterns toward more intensive and combination therapies in ACS patients, improving LDL-C control. These findings support the role of healthcare policy in enhancing guideline-based care and cardiovascular risk reduction.

Related Resources & Content

1. Chinese Cardiovascular Health Alliance (CCHA) Database Studies 2015-2022 -- Real-world data on ACS treatment
2. Expert Consensus on Clinical Pathway for Blood Lipid Management in ACS by Chinese College of Cardiovascular Physician 2021
3. National Healthcare Insurance Policy 2022 -- PCSK9i Reimbursement in China